The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period ...
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the ...
Rachel Kondo, creator and head writer of the hit series Shogun, has never shied away from confronting life’s most difficult ...
Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for patients with all ...
In the phase 1/2 INSPIRE DUCHENNE trial, data from the first 3 patients dosed revealed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple ...
Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...
6don MSN
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.
An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment. Colton Belluzzo was diagnosed with a form of muscular dystrophy when ...
Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback